Delaware-based NiKang Therapeutics Inc. completed an oversubscribed $200 million series C financing. Last year, the company received $50 million in series B financing. “We are thrilled to have such an outstanding group of investors as our shareholders” said Zhenhai Gao, CEO of NiKang. “Their
Delaware-based NiKang Therapeutics Inc. completed an oversubscribed $200 million series C financing. Last year, the company received $50 million in series B financing. “We are thrilled to have such an outstanding group of investors as our shareholders” said Zhenhai Gao, CEO of NiKang. “Their
Researchers launched the Health Equity Tracker, a tool which gathers and analyzes data on health disparities. It aims to fill in data gaps on inequities to empower local advocates and communities. (STAT)
NiKang Therapeutics has brought in $200 million in Series C funding from investors including RA Capital Management and Perceptive. The biotech works on small molecule R&D in oncology. (Endpoints News)
Large anti-vaccination efforts across the country appear to have a common link: Help from New York law firm Siri & Glimstad. The firmâs work is part of a coordinated â and legal â effort to fight vaccine mandates as the U.S. reopens. (The Washington Post)
NiKang Therapeutics Appoints Gary Yeung, CFA, to Board of Directors einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.